530 related articles for article (PubMed ID: 23700851)
21. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
22. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
23. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
24. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
[TBL] [Abstract][Full Text] [Related]
25. Emerging treatment options for uterine fibroids.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
27. Vilaprisan for treating uterine fibroids.
Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
[TBL] [Abstract][Full Text] [Related]
28. Uterine fibroid management: from the present to the future.
Donnez J; Dolmans MM
Hum Reprod Update; 2016 Nov; 22(6):665-686. PubMed ID: 27466209
[TBL] [Abstract][Full Text] [Related]
29. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
30. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
31. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
32. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
[TBL] [Abstract][Full Text] [Related]
33. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
34. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
[TBL] [Abstract][Full Text] [Related]
35. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
36. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
37. Ulipristal acetate: in uterine fibroids.
Croxtall JD
Drugs; 2012 May; 72(8):1075-85. PubMed ID: 22568731
[TBL] [Abstract][Full Text] [Related]
38. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB).
Yin K; Whitaker L; Hojo E; McLenachan S; Walker J; McKillop G; Stubbs C; Priest L; Cruz M; Roberts N; Critchley H
Hum Reprod Open; 2023; 2023(3):hoad021. PubMed ID: 37304815
[TBL] [Abstract][Full Text] [Related]
39. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
40. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP; Duggan ST
Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
